Lebeaut-Alexandre was appointed Executive Vice-President, R&D, and Chief Scientific Officer in April 2017. Dr. Lebeaut joined Ipsen in 2013 as Senior Vice President, Chief Development Officer, Global Drug Development and was appointed Interim Head of R&D in December 2016. He earned his M.D. from Paris Diderot University and specialized in Pediatrics at Paris Descartes University. Before joining Ipsen, he held several global leadership positions in Clinical Development and Medical Affairs with biopharmaceutical companies including Axcan Pharmaceuticals, Sanofi, Novartis and the Schering Plough Research Institute. Lebeaut-Alexandre was appointed Executive Vice-President, R&D, and Chief Scientific Officer in April 2017. Dr. Lebeaut joined Ipsen in 2013 as Senior Vice President, Chief Development Officer, Global Drug Development and was appointed Interim Head of R&D in December 2016. He earned his M.D. from Paris Diderot University and specialized in Pediatrics at Paris Descartes University. Before joining Ipsen, he held several global leadership positions in Clinical Development and Medical Affairs with biopharmaceutical companies including Axcan Pharmaceuticals, Sanofi, Novartis and the Schering Plough Research Institute.

Drug Development